



CLAIMS


1. A uracil derivative represented by the general formula (I):



wherein X represents a group selected from NHCO, NHCH₂, CO, CONH and CH₂NH; R¹ represents a hydrogen atom or a substituted or unsubstituted alkyl group of 1 to 6 carbon atoms; R² represents the general formula (II) or (III):



(II)



(III)

wherein m is 0 or 1, n is an integer of 1 to 3, Y is OH or NH₂, and each dotted line indicates a bonding position, provided that when R² represents the general formula (III), X represents NHCO or NHCH₂; R³ and R⁴ independently represent a hydrogen atom or an alkyl group of 1 to 6 carbon atoms; and Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions, a substituted or substituted heteroaryl group or a bicyclic aromatic

group,

or a pharmaceutically acceptable salt thereof.


2. A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^2 represents the general formula (II) in the general formula (I).
3. A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^2 represents the general formula (III) in the general formula (I).
4. A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).
5. A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).
6. A uracil derivative or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein Ar represents a bicyclic aromatic group in the general formula (I).
7. A uracil derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein X represents NHCO in the general formula (I).
8. A pharmaceutical composition for the

treatment of allergic diseases comprising a uracil derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 as an active ingredient.


9. A pharmaceutical composition for the treatment of pruritus comprising a uracil derivative or a pharmaceutically acceptable salt thereof according to any one of claim 1 to 7 as an active ingredient.

ABSTRACT


There are provided a uracil derivative represented by the general formula (I):



wherein X represents a group selected from NHCO, NHCH₂, CO, CONH and CH₂NH; R¹ represents a hydrogen atom or a substituted or unsubstituted alkyl group of 1 to 6 carbon atoms; R² represents the general formula (II) or (III):



(II)



(III)

wherein m is 0 or 1, n is an integer of 1 to 3, Y is OH or NH₂, and each dotted line indicates a bonding position, provided that when R² represents the general formula (III), X represents NHCO or NHCH₂; R³ and R⁴ independently represent a hydrogen atom or an alkyl group of 1 to 6 carbon atoms; and Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions, a substituted or unsubstituted heteroaryl group or a bicyclic aromatic group,

or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for the treatment of, in particular, allergic diseases in which a type IV allergic reaction participates, which comprises the above-mentioned uracil derivative or pharmaceutically acceptable salt thereof as an active ingredient, that is, there are provided a novel compound useful for treating various allergic diseases, in particular, diseases in which a type IV allergic reaction participates, and a pharmaceutical composition for the treatment of allergic diseases comprising this compound as an active ingredient.